Cover Image
市場調查報告書

色素沉着絨毛結節性滑膜炎:開發中產品分析

Pigmented Villonodular Synovitis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 360914
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
色素沉着絨毛結節性滑膜炎:開發中產品分析 Pigmented Villonodular Synovitis - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 51 Pages
簡介

本報告提供色素沉着絨毛結節性滑膜炎治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

色素沉着絨毛結節性滑膜炎概要

治療藥的開發

  • 開發中產品的概要

色素沉着絨毛結節性滑膜炎:企業開發中的治療藥

色素沉着絨毛結節性滑膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

色素沉着絨毛結節性滑膜炎:企業開發中的產品

色素沉着絨毛結節性滑膜炎治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Novartis AG
  • Plexxikon Inc.

色素沉着絨毛結節性滑膜炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

色素沉着絨毛結節性滑膜炎:最近的開發平台趨勢

色素沉着絨毛結節性滑膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8097IDB

Summary

Global Markets Direct's, 'Pigmented Villonodular Synovitis - Pipeline Review, H1 2016', provides an overview of the Pigmented Villonodular Synovitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis
  • The report reviews pipeline therapeutics for Pigmented Villonodular Synovitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pigmented Villonodular Synovitis therapeutics and enlists all their major and minor projects
  • The report assesses Pigmented Villonodular Synovitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pigmented Villonodular Synovitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pigmented Villonodular Synovitis Overview
  • Therapeutics Development
    • Pipeline Products for Pigmented Villonodular Synovitis - Overview
  • Pigmented Villonodular Synovitis - Therapeutics under Development by Companies
  • Pigmented Villonodular Synovitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Pigmented Villonodular Synovitis - Products under Development by Companies
  • Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd.
    • Five Prime Therapeutics, Inc.
    • Novartis AG
    • Plexxikon Inc.
  • Pigmented Villonodular Synovitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • emactuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FPA-008 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCS-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-73086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pigmented Villonodular Synovitis - Recent Pipeline Updates
  • Pigmented Villonodular Synovitis - Product Development Milestones
    • Featured News & Press Releases
      • May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis
      • Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis
      • Jul 13, 2015: Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis
      • Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis
      • May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting
      • May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pigmented Villonodular Synovitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pigmented Villonodular Synovitis - Pipeline by Five Prime Therapeutics, Inc., H1 2016
  • Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H1 2016
  • Pigmented Villonodular Synovitis - Pipeline by Plexxikon Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pigmented Villonodular Synovitis Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

  • Number of Products under Development for Pigmented Villonodular Synovitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top